Authors

  • Маржонабону Атауллаева

DOI:

https://doi.org/10.71337/inlibrary.uz.science-research.139830

Keywords:

metabolic syndrome hs-CRP inflammation subclinical atherosclerosis cardiovascular risk.

Abstract

This study is aimed at assessing the diagnostic significance of highly sensitive C-reactive protein (hs-CRP) in identifying early cardiovascular complications in patients with metabolic syndrome (MS). 120 patients were examined, divided into three clinical groups: MS without cardiovascular complications, MS with subclinical atherosclerosis, and MS with manifest complications (stenosis, arrhythmia, cardiomyopathy). Laboratory evaluation included the determination of hs-CRP, lipid spectrum, visceral obesity index, and carotid artery dopplerography. It was established that an increase in hs-CRP ≥ 3 mg/l is associated with a 3.2 times increase in the risk of cardiovascular complications. ROC analysis showed high diagnostic accuracy of hs-CRP (AUC=0.84; sensitivity - 81%; specificity - 78%). hs-CRP should be considered as an accessible early marker of inflammation and a prognostic indicator in high-risk patients.

References

Кириченко Андрей Аполлонович, Полякова Ольга Александровна, & Дубовская Ирина Николаевна (2021). Уровни высокочувствительного с-реактивного белка у работающих мужчин молодого и среднего возраста. Consilium Medicum, 23 (1), 99-102.

Koziarska-Rościszewska M., Podgórski M., Chudzik M., et al. High-sensitivity C-reactive protein relationship with metabolic syndrome and its components in hypertensive patients. Life (Basel). 2021;11(8):742.

Mazidi M., Toth P.P., Banach M. C-reactive protein is associated with prevalence of the metabolic syndrome, hypertension, and diabetes mellitus in US adults. Angiology. 2018;69(5):438–442.

Mirhafez S.R., Ebrahimi M., Saberi Karimian M., et al. Serum high-sensitivity C-reactive protein as a biomarker in patients with metabolic syndrome: evidence-based study with 7284 subjects. European Journal of Clinical Nutrition. 2016;70(11):1298–1304.

Shah A.D., Langenberg C., Rapsomaniki E., et al. Type 2 diabetes and CVD risk: a linked electronic health record cohort study. Lancet Diabetes Endocrinol. 2015;3(2):105–113.

Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., ... & Tsao, C. W. (2021). Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation, 143(8), e254–e743. https://doi.org/10.1161/CIR.0000000000000950

World Health Organization. Cardiovascular diseases (CVDs). Fact sheet. Geneva: WHO; 2023.